Gen­fit, Ipsen tout piv­otal tri­al read­out for rare liv­er dis­ease, head to­ward FDA and EMA sub­mis­sions

Gen­fit and Ipsen an­nounced Fri­day morn­ing that their ex­per­i­men­tal treat­ment elafi­bra­nor helped pa­tients with pri­ma­ry bil­iary cholan­gi­tis, a rare liv­er dis­ease, see a de­crease in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER